Ju Suhyun, Jung Youn Joo, Lee Seungju, Kang Seok Kyeong, Ryu Miri, Kim Jee Yeon, Nam Kyung Jin, Lee Kyeyoun, Joo Ji Hyeon, Jeon Youngkyung, Kim Jae Joon, Kim Ji Hoon, Nam Su Bong, Yun Mi Sook, Kim Hyun Yul
Department of Surgery, Research Institute for Convergence of Biomedical Science and Technology, Pusan National University Yangsan Hospital, Pusan National University School of Medicine, Yangsan, Republic of Korea.
Department of Pathology, Pusan National University Yangsan Hospital, Pusan National University School of Medicine, Yangsan, Republic of Korea.
Oncology. 2025 Jan 30:1-11. doi: 10.1159/000543730.
Chemotherapy can cause sleep disorders, anxiety, depression, and decreased quality of life (QoL). This study aimed to compare sleep, anxiety, depression, and QoL during chemotherapy in patients with breast cancer to provide appropriate treatment at the appropriate time.
This prospective study included patients with breast cancer who received chemotherapy at Pusan National University Yangsan Hospital. We used three self-reporting questionnaires regarding quality of sleep (QoS), anxiety, depression, and QoL. QoL was measured using the Pittsburgh Sleep Quality Index, anxiety using the Beck Anxiety Inventory, depression using the Beck Depression Inventory, and QoL using the Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form. Patients were assessed before, after, and during chemotherapy.
In total, 55 patients were enrolled in this study, of whom 49 completed three self-reporting questionnaires. Anxiety, depression, QoS, and QoL varied during the study. Anxiety, depression, and QoL scores were lowest at the end of chemotherapy (p < 0.005). However, QoS scores were lowest at the beginning of chemotherapy (p < 0.005). Cancer subtype (triple-negative vs. luminal type), T stage, type of breast surgery (breast-conserving surgery vs. mastectomy), and chemotherapy type (adjuvant vs. neoadjuvant) did not show a relationship with QoL, anxiety, depression, or QoS; however, age exhibited differences in all four areas. Patients aged >50 years experienced more sleep disturbances, anxiety, depression, and a decreased QoL. In addition, anxiety was increased during chemotherapy in patients with lymph node metastasis.
Patients with breast cancer experience sleep disturbances, anxiety, depression, and low QoL during chemotherapy. During chemotherapy, these symptoms are often overlooked owing to the side effects of chemotherapy. Proper treatment and emotional support will help patients improve their QoL, anxiety, depression, and QoL.
化疗可导致睡眠障碍、焦虑、抑郁及生活质量（QoL）下降。本研究旨在比较乳腺癌患者化疗期间的睡眠、焦虑、抑郁及生活质量，以便在适当的时候提供恰当的治疗。
这项前瞻性研究纳入了在釜山国立大学梁山医院接受化疗的乳腺癌患者。我们使用了三份关于睡眠质量（QoS）、焦虑、抑郁及生活质量的自我报告问卷。使用匹兹堡睡眠质量指数测量睡眠质量，使用贝克焦虑量表测量焦虑，使用贝克抑郁量表测量抑郁，使用生活质量享受与满意度问卷简表测量生活质量。在化疗前、化疗后及化疗期间对患者进行评估。
本研究共纳入55例患者，其中49例完成了三份自我报告问卷。在研究期间，焦虑、抑郁、睡眠质量及生活质量均有所变化。化疗结束时焦虑、抑郁及生活质量评分最低（p<0.005）。然而，睡眠质量评分在化疗开始时最低（p<0.005）。癌症亚型（三阴性与管腔型）、T分期、乳房手术类型（保乳手术与乳房切除术）及化疗类型（辅助化疗与新辅助化疗）与生活质量、焦虑、抑郁或睡眠质量均无相关性；然而，年龄在所有四个方面均表现出差异。年龄>50岁的患者睡眠障碍、焦虑、抑郁更严重，生活质量更低。此外，有淋巴结转移的患者在化疗期间焦虑增加。
乳腺癌患者在化疗期间会出现睡眠障碍、焦虑、抑郁及生活质量低下的情况。在化疗期间，由于化疗的副作用，这些症状常常被忽视。恰当的治疗及情感支持将有助于患者改善睡眠质量、焦虑、抑郁及生活质量。
